federal_register: 2016-11846

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2016-11846 Diabetes Outcome Measures Beyond Hemoglobin A1c: CDER Public Workshop Notice The Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER), is sponsoring a public workshop entitled "Diabetes Outcome Measures Beyond Hemoglobin A1c (HbA1c)." The purpose of this public workshop is to have a forum for dialogue with the public, patients, patient advocacy groups and industry to gain greater appreciation on the extent to which the current regulatory paradigm for antidiabetic drug therapies addresses the needs of patients with diabetes and to identify additional outcomes, beyond HbA1c, that are of direct relevance and importance to patients living with the disease. 2016-05-19 2016 5 https://www.federalregister.gov/documents/2016/05/19/2016-11846/diabetes-outcome-measures-beyond-hemoglobin-a1c-cder-public-workshop https://www.govinfo.gov/content/pkg/FR-2016-05-19/pdf/2016-11846.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER), is sponsoring a public workshop entitled "Diabetes Outcome Measures Beyond Hemoglobin A1c (HbA1c)." The purpose of this public workshop is to have a forum for...  

Links from other tables